A Phase 1 Randomized, Placebo- and Active-controlled, Observer-blind Study in Older Adults With Run-in in Young Adults to Evaluate the Safety, Reactogenicity, and Immunogenicity of Four Dose Levels of VXB-241, A Molecular Clamp Stabilized Prefusion F Glycoprotein Subunit Bivalent Vaccine Candidate for the Prevention of Lower Respiratory Tract Disease Caused by Respiratory Syncytial Virus (RSV) And Human Metapneumovirus (HMPV)
Latest Information Update: 11 Jun 2025
At a glance
- Drugs Respiratory syncytial virus vaccine adjuvanted (Primary) ; VXB 241 (Primary)
- Indications Metapneumovirus infections; Respiratory syncytial virus infections
- Focus Adverse reactions; Pharmacodynamics; Proof of concept
- Sponsors Vicebio
Most Recent Events
- 31 Jan 2025 Status changed from recruiting to active, no longer recruiting.
- 21 Nov 2024 According to Vicebio Media Realease, company is progressing into the second stage of its clinical study of VXB-241 and is now enrolling individuals aged 60 years of age and above.
- 23 Sep 2024 According to Vicebio Media Realease, the company has Commenced this Phase I clinical study of bivalent vaccine targeting both Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV). Initial clinical readouts of the Phase 1 study are expected mid 2025.